(Date:9/5/2008)...Y., Sept. 5 /PRNewswire/ -- Tonight is a momentous...entertainment industry,executives, celebrities and...advocacy join forces to Stand Up to Cancer. This c...8:00 p.m. to 9:00 p.m. ET on the three,networks --...orm to elevate,the discussion about cancer and the...
(Date:9/5/2008)... /PRNewswire/ -- EthicAd, a nonprofit organization...er education, announces,the launch of a new FDA We...nderstand direct-to-consumer (DTC) advertising of ...t Prescription Drug Advertising," is,hosted by the... was,developed by the FDA in partnership with Ethi...
(Date:9/5/2008)... sorafenib helps reverse disease resistance to ant...HealthDay News) -- The drug sorafenib may help "re...ormonal drugs, Georgetown University Medical Cent...tor or progesterone-receptor positive (ER or PR po...hormonal medicines, such as aromatase inhibitors, ...
(Date:9/5/2008)...cer risk prediction models are enhanced by taking ... DNA repair capacity, according to research teams ...M. D. Anderson Cancer Center in two complementary ... Prevention Research . , In the first study to f...e results based on increased exposure to certain r...
Breaking Medicine News(10 mins):Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3(Date:9/4/2008)...INGHAM, Ala., Sept. 4 /- Southern Res...Institutes of Health (NIH) has selected,the organi...r Libraries,Probe Production Center Network (MLPCN...- is part of the Molecular Libraries Program which...ntific knowledge of the human,genome and validate ...
(Date:9/4/2008)... cohort demonstrates potent antiviral activity and...ofile -, CAMBRIDGE, Mass., Sept. 4 /PRNewswire-Fi... IDIX ), a biopharmaceutical company engaged,in th...ment of human viral,and other infectious diseases,...f-concept study evaluating IDX899, a non-nucleosid...
(Date:9/3/2008)...ays: Wrong Question Asked. Wrong Children Studied....PRNewswire-USNewswire/ -- A Centers for Disease,Co...aims there is no link,between the MMR vaccine and ... this study does nothing to dispel the growing pub...aises several questions concerning design,and meth...
(Date:9/3/2008)... September is National Vascular Disease Awarenes...e/ -- Diffusion Pharmaceuticals,LLC, a clinical-st...rugs,for the treatment of unmet medical needs, ann...in a Phase I/II clinical trial of its lead drug,ca... designated NCT00725881,on the clinicaltrials.gov ...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4China Clean Energy Updates Business Outlook 6279 1China Clean Energy Updates Business Outlook 6279 2China Clean Energy Updates Business Outlook 6279 3New York Resident Elected President of Lions Clubs International 22871 1New York Resident Elected President of Lions Clubs International 22871 2Medical Machines Online Announces the Overstock and Release of a New ECG Machine 22868 1Medical Machines Online Announces the Overstock and Release of a New ECG Machine 22868 2Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 22865 1Urgent Care Provider NextCare Introduces CareForToday Medical Insurance Plan 22865 2...file and Excellent,Pharmacokinetic Properties -, R...swire/ --,CeNeRx BioPharma, Inc., a clinical stage... treatments for diseases of the central,nervous sy...e I,clinical trial of Tyrima(TM), its lead candida... this study, Tyrima was safe and well,tolerated. T...
..., 2007--Inflazyme,Pharmaceuticals Ltd. (TSX: IZP).... results of the Phase 2b CAPSICS study with,IPL512...between,patients who received drug or placebo. How...and consistent across a number of,the end-points, ...,external experts to determine if anything untowar...
Other Medicine Technology:CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 2CeNeRx BioPharma Announces Positive Phase I Results in First Human,Trial of Third Generation RIMA Antidepressant 3Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 2Inflazyme Announces Outcome of Review of Phase 2b Asthma Study:,Potential Mitigating Factors Identified which Prevent Clear,Interpretation of Results 3...nts with,predominantly classic subfoveal choroid... the Opal Photoactivator from,Lumenis. Developed...or injection) therapy, the Opal Photoactivator,o...tures,that ensure the highest level of patient c...
Features soft, low friction sheath that extends beyond the tip.
Designed to retain the desired curve during oral intubation.
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box.
Medicine Products: